StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value
$3.05+0.09 (+3.04%)

Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –

Protalix BioTherapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Protalix BioTherapeutics's price to book ratio was 3.6× on Nov 11, 2026, against 2.9× a year earlier. Over the last 5 years it ranged from 2.5× to 178.3×, with a median of 3.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.6×+0.7
2025Dec 31, 20252.9×−1.6
2024Dec 31, 20244.6×+1.3
2023Dec 29, 20233.2×−159.1
2022Jan 31, 2022162.3×+2.0
2021Dec 31, 2021160.3×+136.6
2016Jul 29, 201623.7×−72.7
2013Jan 31, 201396.4×−1.5
2012Dec 31, 201297.9×–

More Protalix BioTherapeutics figures

See a number that looks wrong?